GlassScriptPhysician profile
Edwin David Gar-El
NPI 1740255728
$26,073.68
in general payments reported to CMS, 2019-2025
78 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,970 · 2020: $4,269 · 2021: $2,528 · 2022: $2,807 · 2023: $2,802 · 2024: $2,268 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,454 · Education: $44.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,454.47 |
| Education | $44.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,379.72 | 2019-2020 | |
| Amgen INC. | $1,792.30 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $1,768.68 | 2019-2025 | |
| Novo Nordisk INC | $1,536.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,234.07 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,170.42 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,046.59 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $1,012.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $624.49 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $592.89 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $545.50 | 2019-2023 | Verquvo, Belsomra, Dificid |
| Otsuka America Pharmaceutical, INC. | $503.49 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $501.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $441.10 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $440.38 | 2019-2025 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Gar-El listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.